



KRIBIOLISA™ Adalimumab (HUMIRA™) ELISA


REF : KBI1015

Ver 3.2

RUO

This Kit has been Calibrated against an International Standard from the National Institute of Biologicals and Control (NIBSC), Potters Bar, Hertfordshire EN6 3QG, UK.

Enzyme Immunoassay for the quantitative determination of Adalimumab in serum, plasma and cell culture supernatant



For Research Use Only. Purchase does not include or carry the right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of KRISHGEN BioSystems is strictly prohibited.







KRISHGEN BioSystems| For US / Europe: toll free +1(888)-970-0827 tel: +1(562)-568-5005

For Asia / India: tel: +91(22)-49198700 Email: sales@krishgen.com



Introduction:


Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor alpha (TNF- α). Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps. Adalimumab binds specifically to (TNF- α) and blocks its interaction with the p55 and p75 cell surface TNF receptors. TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis, including juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased levels of TNF are also found in psoriasis (Ps) plaques.

Intended Use:

The KRIBIOLISA™ Adalimumab (Humira™) ELISA is used as an analytical tool for quantitative determination of Adalimumab in serum, plasma and cell culture supernatant.

Principle:

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Adalimumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Adalimumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Adalimumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Adalimumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.



Materials Provided:

Part	Description	Qty
Anti-Adalimumab Coated Microtiter Plate	96 well polystyrene microplate (12 strips of 8 wells) coated with Anti-Adalimumab monoclonal antibody.	1 x 96 wells
Adalimumab Standard	Recombinant Adalimumab in a buffered protein base with preservative sodium azide—lyophilized (1 ug/ml)	2 vials
Anti-Adalimumab:HRP Conjugate	Anti-Adalimumab conjugated to Horseradish Peroxidase with protein stabilizer and preservatives 0.02% methylisothiazolone and 0.02% bromonitrodioxane.	12 ml
(1X) Sample Diluent	Buffered protein base with preservative thiomersol < 0.01%	2 x 50 ml
(1X) Standard Diluent	Buffered protein base with 1:1000 dilution human serum and preservative sodium azide < 0.01%	10 ml
(20X) Wash Buffer	20-fold concentrated solution of buffered surfactant with preservative thiomersol < 0.01%. May turn yellow over time.	25 ml
TMB Substrate	Stabilized chromogen	12 ml
Stop Solution	2N sulfuric acid	12 ml
Instruction Manual		1 no

Materials to be provided by the End-User:

- 1. Microtiter Plate Reader able to measure absorbance at 450 nm.
- 2. Adjustable pipettes and multichannel pipettor to measure volumes ranging from 25µl to 1000µl

3. Deionized (DI) water



- 4. Wash bottle or automated microplate washer
- 5. Graph paper or software for data analysis
- 6. Timer
- 7. Absorbent Paper

Handling/Storage:

- 1. All reagents should be stored at 2°C to 8°C for stability.
- 2. All the reagents and wash solutions should be used within 12 months from manufacturing date.
- 3. Before using, bring all components to room temperature (18-25°C). Upon assay completion ensure all components of the kit are returned to appropriate storage conditions.
- 4. The Substrate is light-sensitive and should be protected from direct sunlight or UV sources.

Health Hazard Warnings:

- 1. Reagents that contain preservatives may be harmful if ingested, inhaled or absorbed through the skin.
- 2. For Research Use Only.



3

Sample Preparation and Storage:

Blood is taken by venipuncture. Serum is separated after clotting by centrifugation. Plasma can be used, too. Lipaemic, hemolytic or contaminated samples should not be run. Repeated freezing and thawing should be avoided. If samples are to be used for several assays, initially aliquot samples and keep at - 20°C.

For Cell Culture Supernatant – If necessary, centrifuge to remove debris prior to analysis. Samples can be stored at -20°C or -80°C. Avoid repeated freeze-thaw cycles.

Preparation Before Use:

Allow samples to reach room temperature prior to assay. Take care to agitate patient samples gently in order to ensure homogeneity.

Test Sample preparation - Samples have to be diluted 1:1000 (v/v), e.g. 1 ul sample + 999 ul sample diluent prior to assay. The samples may be kept at 2 - 8°C for up to three days. Long-term storage requires -20°C.

Reagent Preparation (all reagents should be diluted immediately prior to use):

- Label any aliquots made with the kit Lot No and Expiration date and store it at appropriate conditions mentioned.
- 2. Bring all reagents to Room temperature before use.
- 3. To make Wash Buffer (1X); dilute 25 ml of 20X Wash Buffer in 475 ml of DI water.
- 4. Standards Preparation: Reconstitute the concentrated Standard lyophilized vial with 1 ml of Standard Diluent to obtain a concentration of 1 ug/ml. Keep the vial for 15 mins with gentle agitation before making further dilutions. Dilute 160 ul of original Standard (1 ug/ml) with 340 ul of Standard Diluent to generate a 320 ng/ml Standard Solution. Prepare further Standards by serially diluting the Standard Solution as per the below table. Use the Standard Diluent as the Zero Standard (Standard No.0).

Standard Concentration	Standard Vial	Dilution Particulars
1 ug/ml	Lyophilized Standard	Lyophilized Standard provided in the Kit + 1ml of Standard Diluent
320 ng/ml	Standard No.7	160 ul Reconstituted Standard (1 ug/ml) + 340 ul Standard Diluent
160 ng/ml	Standard No.6	250 ul Standard No.7 + 250 ul Standard Diluent
80 ng/ml	Standard No.5	250 ul Standard No.6 + 250 ul Standard Diluent
40 ng/ml	Standard No.4	250 ul Standard No.5 + 250 ul Standard Diluent
20 ng/ml	Standard No.3	250 ul Standard No.4 + 250 ul Standard Diluent
10 ng/ml	Standard No.2	250 ul Standard No.3 + 250 ul Standard Diluent
5 ng/ml	Standard No.1	250 ul Standard No.2 + 250 ul Standard Diluent
0 ng/ml	Standard No.0	Only Standard Diluent

KRIBIOLISA™ Adalimumab (Humira™) ELISA



Use the Standards immediately upon reconstitution. Discard balance standard after use. Do not store them for further experiments.

Procedural Notes:

- 1. In order to achieve good assay reproducibility and sensitivity, proper washing of the plates to remove excess un-reacted reagents is essential.
- 2. High Dose Hook Effect may be observed in samples with very high concentrations of Adalimumab. High Dose Hook Effect is due to excess of antibody for very high concentrations of Adalimumab present in the sample. High Dose Hook effect is most likely encountered from samples early in the purification process. If Hook Effect is possible, the samples to be assayed should be diluted with a compatible diluent. Thus if the Adalimumab concentration of the undiluted sample is less than the diluted sample, this may be indicative of the Hook Effect.
- 3. Avoid assay of Samples containing sodium azide (NaN₃), as it could destroy the HRP activity resulting in under-estimation of the amount of Adalimumab.
- 4. It is recommended that all Standards and Samples be assayed in duplicates.
- 5. Maintain a repetitive timing sequence from well to well for all the steps to ensure that the incubation timings are same for each well.
- 6. If the Substrate has a distinct blue color prior to use it may have been contaminated and use of such substrate can lead to compromisation of the sensitivity of the assay.
- 7. The plates should be read within 30 minutes after adding the Stop Solution.
- 8. Make a work list in order to identify the location of Standards and Samples.

Assay Procedure:

- 1. It is strongly recommended that all Standards and Samples be run in duplicates or triplicates. A standard curve is required for each assay. All steps must be performed at 37°C
- 2. Pipette 100 ul of Standards or diluted Samples into the respective wells.
- 3. Cover the plate and incubate for 60 minutes at 37°C
- 4. Aspirate and wash plate 4 times with **Wash Buffer (1X)** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.
- 5. Add 100 ul of Anti-Adalimumab:HRP Conjugate into each well.
- 6. Cover the plate and incubate for 60 minutes at 37°C
- 7. Aspirate and wash plate 4 times with **Wash Buffer (1X)** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.
- 8. Add 100 ul of TMB Substrate in each well.
- 9. Incubate the plate at 37°C for 30 minutes in dark. DO NOT SHAKE or else it may result in higher backgrounds and worse precision. Positive wells should turn bluish in color.
- 10. Pipette out 100 ul of Stop Solution. Wells should turn from blue to yellow in color.
- 11. Read the absorbance at 450 nm with a microplate reader.

Calculation of Results:

Determine the Mean Absorbance for each set of duplicate or triplicate Standards and Samples. Using Semi-Log graph paper, plot the average value (absorbance 450nm) of each standard on the Y-axis versus the corresponding concentration of the standards on the X-axis. Draw the best fit curve through the standard points. To determine the unknown Adalimumab concentrations, find the unknown's Mean Absorbance value on the Y-

KRIBIOLISA™ Adalimumab (Humira™) ELISA



5

axis and draw a horizontal line to the standard curve. At the point of intersection, draw a vertical line to the X-axis and read the Adalimumab Concentration. If samples were diluted, multiply by the appropriate dilution factor. Software which is able to generate a cubic spline curve-fit is best recommended for automated results.

Note:


It is recommended to repeat the assay at a different dilution factor in the following cases:

- If the sample absorbance value is below the first standard.
- If the absorbance value is equivalent or higher than the 320 ng/ml standard.

Typical Data

Standards (ng/ml)	Abs A	Interpolated Conc	% Recov Ag Actual conc
0	0.202		
5	0.456	5.3	105.1
10	0.649	10.0	99.9
20	0.978	20.4	102.1
40	1.333	37.7	94.3
80	1.781	82.6	103.3
160	2.092	170.6	106.6
320	2.245	294.0	91.9

Typical Graph



Quality Control:

It is recommended that for each laboratory assay appropriate quality control samples in each run to be used to ensure that all reagents and procedures are correct.

Performance Characteristics of the Kit:

This kit has been validated as per EMA/FDA guidelines in line with ICH Code for Harmonization of Biological Assays.

Sensitivity:

Limit Of Detection: It is defined as the lowest detectable concentration corresponding to a signal of Mean of '0' standard plus 2* SD.

10 replicates of '0' standards were evaluated and the LOD was found to be less than 4.8 ng/ml

Calibration:

This Kit has been Calibrated against an International Standard from the National Institute of Biologicals and Control (NIBSC), Potters Bar, Hertfordshire EN6 3QG, UK. 1 ng of supplied standard equals 0.01 IU of TNF-alpha binding activity. Please note that the calibration is lot specific.

The Standards provided in the kit are also calibrated against commercially sourced Humira™ and alternate biosimilar recombinant Adalimumab injection.



Precision:

Precision is defined as the percent coefficient of variation (%CV) i.e. standard deviation divided by the mean and multiplied by 100. Assay precision was determined by both intra (n=5 assays) and inter assay (n=5 assays) reproducibility on two pools with low (5ng/ml), medium (40ng/ml) and high (320ng/ml) concentrations. While actual precision may vary from laboratory to laboratory and technician to technician, it is recommended that all operators achieve precision below these design goals before reporting results.

Pool	Intra Assay %CV	Inter Assay %CV
Low	<10%	<10%
Medium	<5%	<5%
High	<5%	<5%

Safety Precautions:

- This kit is For Research Use only. Follow the working instructions carefully.
- The expiration dates stated on the kit are to be observed. The same relates to the stability stated for reagents
- Do not use or mix reagents from different lots.
- Do not use reagents from other manufacturers.
- Avoid time shift during pipetting of reagents.
- All reagents should be kept in the original shipping container.
- Some of the reagents contain small amount of sodium azide (< 0.1 % w/w) as preservative. They must not be swallowed or allowed to come into contact with skin or mucosa.



- Source materials maybe derived from human body fluids or organs used in the preparation of this kit were tested and found negative for HBsAg and HIV as well as for HCV antibodies. However, no known test guarantees the absence of such viral agents. Therefore, handle all components and all patient samples as if potentially hazardous.
- Since the kit contains potentially hazardous materials, the following precautions should be observed
- Do not smoke, eat or drink while handling kit material
- Always use protective gloves
- Never pipette material by mouth
- Wipe up spills promptly, washing the affected surface thoroughly with a decontaminant.
- In any case GLP should be applied with all general and individual regulations to the use of this kit.

References:

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial ... JF Colombel, WJ Sandborn, P Rutgeerts, R Enns... - Gastroenterology, 2007 - Elsevier

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ... ME Weinblatt, EC Keystone, DE Furst... - Arthritis & ..., 2003 - Wiley Online Library

randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with ... FC Breedveld, MH Weisman... - ... : Official Journal of ..., 2006 - Wiley Online Library

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I Trial ... SB Hanauer, WJ Sandborn, P Rutgeerts, RN Fedorak... - Gastroenterology, 2006 - Elsevier

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active ... EC Keystone, AF Kavanaugh, JT Sharp... - Arthritis & ..., 2004 - Wiley Online Library

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial ... WJ Sandborn, SB Hanauer, PJ Rutgeerts, RN Fedorak... - Gut, 2007 - gut.bmj.com

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial ... WJ Sandborn, P Rutgeerts, R Enns... - Annals of internal ..., 2007 - Am Coll Physicians

Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial ... A Menter, SK Tyring, K Gordon, AB Kimball... - Journal of the American ..., 2008 - Elsevier

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis ... WJ Sandborn, G Van Assche, W Reinisch, JF Colombel... - Gastroenterology, 2012 - Elsevier

KRIBIOLISA™ Adalimumab (Humira™) ELISA



Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial ... PJ Mease, DD Gladman, CT Ritchlin... - ... : Official Journal of ..., 2005 - Wiley Online Library

distributed in the US/Canada by: **EAGLE BIOSCIENCES, INC.**


20A NW Blvd, Suite 112 Nashua, NH 03063

Phone: 617-419-2019 FAX: 617-419-1110 www.EagleBio.com • info@eaglebio.com





SCHEMATIC ASSAY PROCEDURE





2. Avoid repeated cool-thaw of the components as there will be a loss of activity and this can affect the results.



3. Pipette 100 ul Standards / diluted Samples into each well.



5. Aspirate and wash wells 4 times with Wash Buffer (1X).





8. Aspirate and wash wells 4 times with **Wash Buffer (1X).**





11. Pipette 100 μl Stop Solution into each well.





Typical Example of a Work List

Well #	Contents	Absorbance at 450nm	Mean Absorbance	ng/ml Adalimumab equivalent
1A 2A	zero std zero std			
1B	5 ng/ml			
2B	5 ng/ml			
1C	10 ng/ml			
2C	10 ng/ml			
1D	20 ng/ml			
2D	20 ng/ml			
1E	40 ng/ml			
2E	40 ng/ml			
1F	80 ng/ml			
2F	80 ng/ml			
1G	160 ng/ml			
2G	160 ng/ml			
1H	320 ng/ml			
2H	320 ng/ml			
3A	Sample			
4A	Gample			
3B	Sample			
4B				

LIMITED WARRANTY

Krishgen Biosystems does not warrant against damages or defects arising in shipping or handling, or out of accident or improper or abnormal use of the Products; against defects in products or components not manufactured by Krishgen Biosystems, or against damages resulting from such non-Krishgen Biosystems made products or components. Krishgen Biosystems passes on to customer the warranty it received (if any) from the maker thereof of such non Krishgen made products or components. This warranty also does not apply to Products to which changes or modifications have been made or attempted by persons other than pursuant to written authorization by Krishgen Biosystems.

THIS WARRANTY IS EXCLUSIVE. The sole and exclusive obligation of Krishgen Biosystems shall be to repair or replace the defective Products in the manner and for the period provided above. Krishgen Biosystems shall not have any other obligation with respect to the Products or any part thereof, whether based on contract, tort, and strict liability or otherwise. Under no circumstances, whether based on this Limited Warranty or otherwise, shall Krishgen Biosystems be liable for incidental, special, or consequential damages.

This Limited Warranty states the entire obligation of Krishgen Biosystems with respect to the Products. If any part of this Limited Warranty is determined to be void or illegal, the remainder shall remain in full force and effect.

Krishgen Biosystems. 2021

THANK YOU FOR USING KRISHGEN PRODUCT!



SYMBOLS KEY

МТР	Anti-Adalimumab Coated Microtiter Plate (12X8 wells)
STD	Adalimumab Standard, lyophilized
HRP CONJ	Conjugate Horseradish Peroxidase
1X STD DIL	(1X) Standard Diluent
1X SAMP DIL	(1X) Sample Diluent
20X WASH BUF	(20X) Wash Buffer
SUB TMB	TMB Substrate
SOLN STOP	Stop Solution
<u> i</u>	Consult Instructions for Use
REF	Catalog Number
	Expiration Date
<i> X</i>	Storage Temperature

distributed in the US/Canada by: EAGLE BIOSCIENCES, INC.

20A NW Blvd, Suite 112 Nashua, NH 03063 Phone: 617-419-2019 FAX: 617-419-1110 www.EagleBio.com info@eaglebio.com

